SSA
MRNS

Schonfeld Strategic Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-67,698
Closed -$119K – 2520
2024
Q3 		$119K Buy
67,698
+37,598
+125% +$52.5K ﹤0.01% 1858
2024
Q2 		$35.2K Buy
+30,100
New +$75.3K ﹤0.01% 1969
2023
Q4 		– Sell
-253,412
Closed -$2.04M – 2327
2023
Q3 		$2.04M Buy
253,412
+103,935
+70% +$865K 0.02% 823
2023
Q2 		$1.62M Buy
149,477
+101,227
+210% +$867K 0.01% 817
2023
Q1 		$333K Buy
+48,250
New +$303K ﹤0.01% 1328
2018
Q4 		– Sell
-10,025
Closed -$401K – 1265
2018
Q3 		$401K Buy
+10,025
New +$285K 0.02% 625
2018
Q1 		– Sell
-52,972
Closed -$1.73M – 1014
2017
Q4 		$1.73M Sell
52,972
-16,327
-24% -$440K 0.14% 204
2017
Q3 		$1.63M Buy
+69,299
New +$777K 0.15% 176

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Schonfeld Strategic Advisors's MRNS Position: Q4 2024 in Review

Schonfeld Strategic Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 67,698 shares — an estimated $119K sold.

Schonfeld Strategic Advisors first reported a position in MRNS in Q3 2017 and held it in 8 quarters. The position peaked at $2.04M in Q3 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Schonfeld Strategic Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 67,698 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $119K.
  • Schonfeld Strategic Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 8 quarters.
  • Schonfeld Strategic Advisors's Marinus Pharmaceuticals, Inc position peaked at $2.04M in Q3 2023.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.